Open AccessAdjuvant therapy for lung neuroendocrine neoplasms
Author(s) -
Robert A. Ramirez,
Katharine Thomas,
Aasems Jacob,
Karen Lin,
Yvette BrenMattison,
Aman Chauhan
Publication year - 2021
Publication title -
world journal of clinical oncology
Language(s) - Uncategorized
Resource type - Journals
ISSN - 2218-4333
DOI - 10.5306/wjco.v12.i8.664
Subject(s) - medicine , adjuvant , adjuvant therapy , stage (stratigraphy) , oncology , lung , lung cancer , neuroendocrine carcinoma , carcinoid tumour , cancer , carcinoma , paleontology , biology
Pulmonary neuroendocrine neoplasms (NENs) represent a minority of lung cancers and vary from slower growing pulmonary carcinoid (PC) tumors to aggressive small cell lung cancer (SCLC). While SCLC can account for up to 15% of lung cancer, PCs are uncommon and represent about 2% of lung cancers. Surgical resection is the standard of care for early-stage PCs and should also be considered in early stage large cell neuroendocrine carcinoma (LCNEC) and SCLC. Adjuvant treatment is generally accepted for aggressive LCNEC and SCLC, however, less well established for PCs. Guidelines admit a lack of trials to support a high-level recommendation for adjuvant therapy. This manuscript will discuss the role for adjuvant therapy in NENs and review the available literature.